having fallen around 45% from $6 and if there's not much fundamentally wrong with this stock then it has to be considered a takeover target at this stage.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025